Bisphosphonates: Prevention of bone metastases in prostate cancer

Recent Results in Cancer Research

Volumn 192, Issue , 2012, Pages 109-126

  Saad, Fred ^a   Lattouf, Jean Baptiste ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Anticancer; Bisphosphonate; Bone metastases; Genitourinary cancer>; Prostate cancer; Zoledronic acid>

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; DOXORUBICIN; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER HORMONE THERAPY; CANCER PREVENTION; CASTRATION RESISTANT PROSTATE CANCER; CHEMOPROPHYLAXIS; DRUG POTENTIATION; HUMAN; ORCHIECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 84858236510     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-21892-7_5     Document Type: Article

References (94)

1. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420-432
2. Amgen Inc (2010a) Xgeva (denosumab) injection package insert. http://www.accessdata.fda. gov/drugsatfda-docs/label/2010/125320s007lbl.pdf. Accessed 8 Feb 2011
3. TM (denosumab) significantly improved bone metastasis-free survival in men with prostate cancer press release. http://wwwext.amgen.com/media/media-pr-detail.jsp?year=2010&releaseID= 1507379. Accessed 8 Feb 2011
4. Amgen Europe BV (2011) XGEVA 120 mg solution for injection summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document.library/ EPAR-Product-Information/human/002173/WC500110381.pdf. Accessed 21 Oct 2011
5. Anand A, Scher HI, Beer TM, et al (2010) Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naive patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. J Clin Oncol 28(suppl):353s, Abstract 4546
6. Berg A, Berner A, Lilleby W et al (2007) Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 120:1603-1609 (Pubitemid 46399343)
7. Bhoopalam N, Campbell SC, Moritz T et al (2009) Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 182:2257-2264
8. Body J-J, Cook R, Costa L, et al (2009) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features poster. Presented at: the IX International Meeting on Cancer Induced Bone Disease, Arlington, 28-31 Oct 2009, Poster 71
9. Boissier S, Ferreras M, Peyruchaud O et al (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949-2954 (Pubitemid 30395820)
10. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342 (Pubitemid 40852708)
11. Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69
12. Brown JE, Lipton A, Cook RJ, et al (2009) N-telopeptide of type I collagen (NTX) correlates with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC) poster. Presented at: American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, Orlando, 26-28 Feb 2009, Poster A66
13. Casey R, Gesztesi Z, Rochford J (2010) Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol 17:5170-5177
14. Choueiri TK, Duh MS, Clement J et al (2010) Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 105:1247-1254
15. Clezardin P, Massaia M (2010) Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 16:3007-3014
16. Clines GA, Guise TA (2008) Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10:e7
17. Clyburn RD, Reid P, Evans CA et al (2010) Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol 65:969-978
18. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176 (Pubitemid 32452017)
19. Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935 (Pubitemid 46223998)
20. Cook RJ, Coleman R, Brown J et al (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12:3361-3367
21. Costa L, Cook R, Body JJ, et al (2009) Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption poster. Presented at: the IX International Meeting on Cancer Induced Bone Disease, Arlington, 28-31 Oct 2009, Poster 50
22. Coxon JP, Oades GM, Kirby RS et al (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94:164-170 (Pubitemid 38980328)
23. Danila DC, Heller G, Gignac GA et al (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053-7058 (Pubitemid 350276887)
24. Danila DC, Anand A, Sung CC, et al (2010) Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy abstract. J Clin Oncol 28(suppl): 375s, Abstract 4635
25. Dearnaley DP, Mason MD, Parmar MK, et al (2009a) Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: long-term results of MRC PR04 & PR05 poster. Presented at: American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, Orlando, 26-28 Feb 2009, Abstract 6
26. Dearnaley DP, Mason MD, Parmar MKB et al (2009b) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10:872-876
27. Diamond TH, Higano CS, Smith MR et al (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100:892-899 (Pubitemid 38222847)
28. Dieli F, Vermijlen D, Fulfaro F et al (2007) Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67: 7450-7457 (Pubitemid 47206575)
29. Donat DA, Pesic JM, Tesanovic SM, et al (2006) Low-dose clodronate as adjunctive therapy in prostate cancer patients with painful bone metastases abstract. Ann Oncol 17(suppl 9):ix156 Abstract 484
30. Ernst DS, Tannock IF, Winquist EW et al (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335-3342 (Pubitemid 46613484)
31. Facchini G, Caraglia M, Morabito A et al (2010) Metronomic administration of zoledronic acid and Taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 10:543-548
32. Fizazi K, Carducci M, Smith M, et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
33. Garcia M, Jemal A, Ward EM, et al (2007) Global cancer facts and figures 2007. American Cancer Society. http://www.cancer.org/acs/groups/content/@nho/ documents/document/globalfactsand figures2007rev2p.pdf. Accessed 8 Feb 2011
34. Greenspan SL, Bone HG, Ettinger MP et al (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326-339 (Pubitemid 351650593)
35. Guise TA (2008) Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 34:S19-S24
36. Harper S, Dansey R (2010) Amgen investor meeting: 2010 ASCO annual meeting. http://phx. corporate-ir.net/External.File?item= UGFyZW50SUQ9NDkyMTh8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1. Accessed 8 Feb 2011
37. Hatoum HT, Lin SJ, Guo A et al (2011) Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 27:55-62
38. Heidenreich A, Bolla M, Joniau S et al (2009) Guidelines on prostate cancer. European Association of Urology. http://www.uroweb.org/fileadmin/tx- eauguidelines/2009/Full/Prostate-Cancer.pdf. Accessed 8 Feb 2011
39. Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132
40. Hering F, Rodrigues PRT, Lipay M (2003) Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol 29:228-233 (Pubitemid 36950028)
41. Hirsh V, Major PP, Lipton A et al (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3:228-236 (Pubitemid 351654321)
42. Israeli RS, Rosenberg SJ, Saltzstein DR et al (2007) The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 5:271-277 (Pubitemid 46867363)
43. Izumi K, Mizokami A, Sugimoto K et al (2009) Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 73:1342-1346
44. Izumi K, Mizokami A, Narimoto K, et al (2010) The role of bone turnover markers in patients with bone metastatic prostate cancer receiving zoledronate infusion poster. Presented at: American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium, San Francisco, 5-7 March 2010, Abstract 196
45. Josson S, Matsuoka Y, Chung LW et al (2010) Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 21:26-32
46. Kollermann J, Weikert S, Schostak M et al (2008) Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 26:4928-4933
47. Koul HK, Koul S, Kumar B, et al (2010) Direct effects of zoledronic acid on hormone-responsive and hormone-refractory prostate cancer cells poster. Presented at: American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium, San Francisco, 5-7 March 2010, Abstract 184
48. Lee RJ, Stott SL, Nagrath S, et al (2009) Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using CTC-chip microfluidic device abstract. J Clin Oncol 27(suppl):271s Abstract 5149
49. Lipton A, Small E, Saad F et al (2002) The new bisphosphonate, zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20(suppl 2):45-54 (Pubitemid 35303443)
50. Lipton A, Seaman J, Zheng M (2004) Efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma poster. Presented at: What is New in Bisphosphonates? Seventh Workshop on Bisphosphonates-From the Laboratory to the Patient, Davos, Switzerland, 24-26 Mar 2004 Abstract 28
51. Lipton A, Cook RJ, Major P et al (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12:1035-1043 (Pubitemid 350007015)
52. Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193-201 (Pubitemid 351976401)
53. Meads MB, Hazlehurst LA, Dalton WS (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14:2519-2526
54. Merck & Co. Inc (2010) Fosamax (alendronate sodium) tablets and oral solution package insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2010/020560s051s055s057, 021575s012s016s018lbl.pdf. Accessed 8 Feb 2011
55. Michaelson MD, Marujo RM, Smith MR (2004) Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res 10: 2705-2708 (Pubitemid 38509145)
56. Morgan C, Lewis PD, Jones RM et al (2007) The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 46:669-677 (Pubitemid 46911908)
57. Morgan TM, Lange PH, Porter MP et al (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15:677-683
58. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593 (Pubitemid 37328925)
59. Naoe M, Ogawa Y, Takeshita K et al (2010) Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res 18:493-501
60. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA et al (2005) Sequence-and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364-371 (Pubitemid 40038702)
61. Noguchi M, Yahara J, Noda S (2003) Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61:993-998 (Pubitemid 36547745)
62. Norton L, Massague J (2006) Is cancer a disease of self-seeding? Nat Med 12:875-878 (Pubitemid 44175132)
63. Novartis Pharmaceuticals Corporation (2008) Reclast (zoledronic acid) injection package insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2008/021817s001lbl.pdf. Accessed 8 Feb 2011
64. Novartis Pharmaceuticals Corporation (2009) Zometa (zoledronic acid) injection package insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2009/021223s018lbl.pdf. Accessed 8 Feb 2011
65. Olmos D, Arkenau HT, Ang JE et al (2009) Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 20:27-33
66. Oudard S, Smith MR, Karsh L et al (2011) Denosumab and bone metastases-free survival in men with castration-resistant prostate cancer: Subgroup analyses from an international, double-blind, randomized phase 3 trial. Presented at: The European Multidisciplinary Cancer Congress. Stockholm, Sweden, 23-27 Sept 2011. Abstract 7003 oral
67. Padalecki SS, Carreon MR, Grubbs B, et al (2002) Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: prevention by zoledronic acid abstract. Presented at: 24th annual meeting of the American Society for Bone and Mineral Research, San Antonio, 20-24 Sept 2002, Abstract SU072
68. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571-573
69. Planas J, Trilla E, Raventos C et al (2009) Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 104:1637-1640
70. Procter & Gamble Pharmaceuticals Inc (2009) Actonel (risedronate sodium) tablets package insert. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/020835s036lbl.pdf. Accessed 8 Feb 2011
71. Rodrigues P, Hering F, Campagnari JC (2004) Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 7:350-354 (Pubitemid 41721795)
72. Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978 (Pubitemid 30413179)
73. Rucci N, Teti A (2010) Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed) 2:907-915
74. Ryan CW, Huo D, Demers LM, et al (2006) Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176:972-978, discussion follows (Pubitemid 44142571)
75. Saad F (2008) New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev 34:183-192 (Pubitemid 351384327)
76. Saad F, Lipton A (2005) Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 96:964-969 (Pubitemid 41531396)
77. Saad F, Lipton A (2007) Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 34(4):S17-S23 (Pubitemid 350192630)
78. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
79. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882 (Pubitemid 38807610)
80. Saad F, Lipton A, Cook R et al (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860-1867 (Pubitemid 47557312)
81. Shiozawa Y, Havens AM, Pienta KJ et al (2008) The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22:941-950 (Pubitemid 351689875)
82. Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948-955
83. Smith MR, Eastham J, Gleason DM et al (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008-2012 (Pubitemid 36576705)
84. Smith MR, Cook RJ, Coleman R et al (2007) Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 70:315-319 (Pubitemid 47362256)
85. Smith MR, Egerdie B, Hernandez Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755
86. Smith MR, Saad F, Coleman R, et al (2009) Denosumab to prolong bone metastases-free survival in men with castrate-resistant prostate cancer: Results of a global phase 3, randomized, double-blind trial. Presented at: American Urological Association Annual Meeting. Washington, DC, 14-19 May 2011. Late Breaking News
87. Soltau J, Zirrgiebel U, Esser N et al (2008) Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 28:933-941 (Pubitemid 351578940)
88. Taxel P, Dowsett R, Richter L et al (2010) Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 106:1473-1476
89. US National Institutes of Health (2008) Zoledronate plus standard therapy compared with placebo plus standard therapy to prevent bone metastases in patients with recurrent prostate cancer that has no symptoms. http://clinicaltrials.gov/ct2/show/NCT00005073. Accessed 8 Feb 2011
90. US National Institutes of Health (2009) RADAR trial-randomised androgen deprivation and radiotherapy. http://clinicaltrials.gov/ct2/show/NCT00193856. Accessed 8 Feb 2011
91. Ullen A, Schwarz S, Lennartsson L et al (2009) Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 43:98-103
92. Weckermann D, Polzer B, Ragg T et al (2009) Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27:1549-1556
93. Yuasa T, Sato K, Ashihara E et al (2009) Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 58:493-502
94. Zaghloul MS, Boutrus R, El-Hossieny H et al (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15: 382-389